BioInvent International AB banner

Company Overview

Business Description

Sector
Health Care
Industry
Biotechnology
Headquarters
Sweden SE
Employees
112
IPO date
Jun 12, 2001

BioInvent International AB is a Swedish biotech company that discovers and develops antibody-based medicines, mainly for cancer. It does not sell consumer products; instead, it creates drug candidates and research tools that are meant to be tested in clinical studies and then licensed or partnered with larger drugmakers. Its work centers on finding antibodies that can help the immune system attack tumors or block signals that cancer cells use to grow.

The company makes money in a few ways. It can receive payments from research collaborations, upfront licensing deals, milestone payments tied to drug development progress, and future royalties if partnered drug candidates reach the market. In some cases, BioInvent also advances its own drug programs, which can create more value if those medicines succeed, but that also means the business depends heavily on long development timelines and scientific results.

What makes BioInvent different is that it sits at the early discovery stage of the drug chain. Instead of manufacturing finished medicines at scale, it focuses on finding promising antibody candidates and then handing them to partners or pushing them through clinical testing itself. Its main customers and counterparties are pharmaceutical companies, research partners, and the healthcare system that would eventually use any approved cancer drugs it helps create.

BioInvent International AB Investor Relations

Address
Ideongatan 1
Lund, Skane
Sweden

Business Segments

Drug discovery platform

BioInvent discovers and designs antibody drugs using its screening and antibody-engineering technology. The company uses this platform to find new drug candidates for its own pipeline and for partners.

Customers and revenue model

Clinical antibody pipeline

BioInvent develops its own antibody-based drug candidates through laboratory testing and clinical trials, mainly in cancer and immune diseases. This work turns early discoveries into potential medicines.

Customers and revenue model

Management

Dr. Martin Welschof Ph.D.

President & CEO

Biography unavailable

Mr. Stefan Ericsson M.B.A.

Chief Financial Officer

Biography unavailable

Ms. Marie Moores M.Sc., R.G.N.

Chief Operating Officer

Biography unavailable

Mr. Kristoffer Rudenholm Hansson

Senior Vice President of Technical Operations

Biography unavailable

Mr. Björn Frendéus

Chief Scientific Officer

Biography unavailable

Ms. Cecilia Hofvander

Senior Director of Investor Relations

Biography unavailable

Dr. Andres McAllister

Chief Medical Officer

Biography unavailable

Ms. Ingrid Teige

Head of Preclinical Research

Biography unavailable

Ms. Sylvie Ryckebusch

Chief Business Officer

Biography unavailable

Dr. Ingunn Munch Lindvig

Senior Vice President of Regulatory Affairs

Biography unavailable

1 / 10